The biosulin equivalence in standard therapy (BEST) study - A multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus

South African Medical Journal

Volumn 103, Issue 7, 2013, Pages 458-460

  Segal, D ^a   Tupy, D ^b   Distiller, L ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Hillbrow Community Hospital   (South Africa)

^c Centre for Diabetes and Endocrinology   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSULIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SOUTH AFRICA; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84879475098     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.6345     Document Type: Article

References (7)

1. International Diabetes Federation. IDF Diabetes Atlas 2012;c2003. http://www.idf.org/diabetesatlas (accessed 9 July 2012).
2. Amod A, Motala A, Levitt N, et al. The 2012 SEMDSA treatment algorithm for type 2 diabetes. JEMDSA 2012;17(1):S36-S40.
3. Home P. Biosimilar insulins. Diabetes Voice 2011;56(2):40-43.
4. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Brit J Diab Vasc Dis 2010;10(2):90-97.
5. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006(2):CD003287.
6. orvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type II diabetes mellitus. Cochrane Database Syst Rev 2007(2):CD005613.
7. Distiller LA, Joffe BI. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 2006;49(11):2793-2794.